시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
인슐린 바이오시밀러 시장 규모, 점유율, 성장 분석 : 유형별, 적응증별, 유통 채널별, 지역별 - 산업 예측(2025-2032년)
Insulin Biosimilars Market Size, Share, Growth Analysis, By Type: (Fast-acting Insulin, Intermediate-acting Insulin), By Indication: (Diabetes Type 1, Diabetes Type 2), By Distribution Channel:, By Region - Industry Forecast 2025-2032
상품코드 : 1630678
리서치사 : SkyQuest
발행일 : 2025년 01월
페이지 정보 : 영문 219 Pages
 라이선스 & 가격 (부가세 별도)
US $ 5,300 ￦ 7,611,000
PDF & Excel (Single User License) help
PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,200 ￦ 8,904,000
PDF & Excel (Multiple User License) help
PDF 및 Excel 보고서를 동일 사업장에서 2-5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 7,100 ￦ 10,197,000
PDF & Excel (Enterprise License) help
PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


한글목차

세계의 인슐린 바이오시밀러 시장 규모는 2023년에 29억 달러에 달하며, 예측 기간(2025-2032년)의 CAGR은 6.2%로, 2024년 30억 8,000만 달러에서 2032년에는 49억 8,000만 달러로 성장할 전망입니다.

인슐린 바이오시밀러 시장은 당뇨병 유병률 증가와 더불어 당뇨병 연구 및 개발(R&D)에 대한 투자 증가로 인해 큰 성장이 예상됩니다. 효과적인 당뇨병 관리의 필요성이 전 세계에서 증가함에 따라 향후 수년간 이러한 제품에 대한 수요가 증가할 것으로 예상됩니다. 혁신적인 인슐린 바이오시밀러에 대한 새로운 임상시험은 시장 확대를 더욱 촉진할 것이며, 오리지널 인슐린 제제의 특허 만료가 임박함에 따라 시장 기업에게 새로운 비즈니스 기회를 제공합니다. 그러나 엄격한 규제 요건과 새로운 바이오시밀러의 임상적 수용을 둘러싼 문제들은 여전히 남아 있으며, 장기적으로 전체 시장 개척에 장애가 될 가능성이 있습니다.

목차

서론

조사 방법

개요

시장 역학과 전망

주요 시장 인사이트

인슐린 바이오시밀러 시장 규모 : 유형별

인슐린 바이오시밀러 시장 규모 : 적응증별

인슐린 바이오시밀러 시장 규모 : 유통 채널별

인슐린 바이오시밀러 시장 규모& CAGR(2025-2032)

경쟁 정보

주요 기업 개요

결론과 권장사항

KSA
영문 목차

영문목차

Global Insulin Biosimilars Market size was valued at USD 2.9 billion in 2023 and is poised to grow from USD 3.08 billion in 2024 to USD 4.98 billion by 2032, growing at a CAGR of 6.2% during the forecast period (2025-2032).

The market for insulin biosimilars is poised for significant growth due to the rising prevalence of diabetes, coupled with increasing investments in diabetes research and development (R&D). The ongoing need for effective diabetes management globally is expected to drive demand for these products in the coming years. New clinical trials for innovative insulin biosimilars will further facilitate market expansion, supported by the impending patent expirations of original insulin products, which presents fresh opportunities for market players. However, challenges remain, including stringent regulatory requirements and issues surrounding the clinical acceptance of new biosimilars, which could hinder overall market development in the long term.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Insulin Biosimilars market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Insulin Biosimilars Market Segmental Analysis

Global Insulin Biosimilars Market is segmented by Type, Indication, Distribution Channel, and region. Based on Type, the market is segmented into Fast-acting Insulin, Intermediate-acting Insulin and Long-acting Insulin. Based on Indication, the market is segmented into Diabetes Type 1 and Diabetes Type 2. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Insulin Biosimilars Market

The Global Insulin Biosimilars market is significantly driven by the impending patent expirations of established originator insulin products. As these long-standing products become less protected, it is expected to increase the demand for innovative new biosimilars. Furthermore, the rising investment in medical research and development is anticipated to open up new avenues for manufacturers of insulin biosimilars, facilitating the introduction of advanced therapeutic options to the market. This combination of patent expirations and heightened R&D activities is poised to transform the competitive landscape, ultimately benefiting patients with more affordable and effective insulin alternatives.

Restraints in the Global Insulin Biosimilars Market

The global insulin biosimilars market faces significant constraints due to complex regulatory mandates imposed by governments and regulatory authorities. These stringent regulations create challenges for new companies aiming to develop and introduce insulin biosimilars to the market. The arduous approval processes and extensive requirements can hinder innovation and slow down the entry of novel products. As a result, many potential developers may find it daunting to navigate the regulatory landscape, ultimately limiting competition and variety within the market. This restrictive environment poses a substantial barrier to the growth and expansion of the insulin biosimilars sector on a global scale.

Market Trends of the Global Insulin Biosimilars Market

The Global Insulin Biosimilars market is witnessing a significant trend towards the adoption of biologic and biosimilar therapies for diabetes management. As patients and healthcare institutions increasingly prioritize cost-effective treatment options, the demand for high-quality insulin biosimilars is rising, presenting lucrative opportunities for suppliers. This shift is fueled by the need for affordable alternatives to traditional insulin therapies, alongside growing awareness of the efficacy and safety of biosimilars. Companies that innovate and develop novel biosimilar products in alignment with this market trend are poised to enhance their market presence and drive revenue growth in the competitive diabetes care landscape.

Table of Contents

Introduction

Research Methodology

Executive Summary

Market Dynamics & Outlook

Key Market Insights

Global Insulin Biosimilars Market Size by Type: & CAGR (2025-2032)

Global Insulin Biosimilars Market Size by Indication: & CAGR (2025-2032)

Global Insulin Biosimilars Market Size by By Distribution Channel: & CAGR (2025-2032)

Global Insulin Biosimilars Market Size & CAGR (2025-2032)

Competitive Intelligence

Key Company Profiles

Conclusion & Recommendations

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기